Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

ABSTRACT:

Objective

To determine clinical and biological variables that predict time to initiation of symptomatic therapy in de novo Parkinson's disease patients.

Methods

Parkinson's Progression Markers Initiative is a longitudinal case-control study of de novo, untreated Parkinson's disease participants at enrolment. Participants contribute a wide range of motor and non-motor measures, including biofluids and imaging biomarkers. The machine learning method of random survival forests was used to examine the ability of baseline variables to predict time to initiation of symptomatic therapy since study enrollment (baseline).

Results

There were 423 PD participants enrolled in PPMI and 33 initial baseline variables. Cross-validation results showed that the three-predictor subset of

SUBMITTER: Simuni T 

PROVIDER: S-EPMC4931714 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature